Avenue Therapeutics Inc (NASDAQ:ATXI) Stock Continues to Consolidate After The Recent Move

October 4, 2021

Avenue Therapeutics Inc (NASDAQ:ATXI) in a statement announced that the group has received Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). Through the second CRL, the company is hoping that it will receive a nod for usage of IV tramadol. In the CRL, the group stated that a delay and the unpredictable onset of analgesia with IV tramadol would not support it as a monotherapy used…

Read More >>